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Introduction
Gold nanoparticles (AuNPs) are proven radiosensitisers at kilovoltage (keV) and megavoltage (MV) photon energies, an effect attributed, in part, to the high mass absorption coefficient of gold. (1) (2) (3) To date, most studies have focused on the impact of nanoparticle size, shape, charge and elasticity on internalisation efficacy, with several authors indicating 50 nm AuNPs are most avidly endocytosed.(4-6) Endocytosis of AuNPs exceeding 10 nm predominantly occurs via the endosomal-lysosomal degradation pathway, while direct pinocytosis dominates for sub 10 nm particles. (4, 7) Achieving sufficient target cell AuNP uptake represents a major barrier to clinical translation. With this in mind we have developed a novel multi-functional AuNP, designed to promote intracellular uptake and overcome endosomal entrapment, thereby improving the radiosensitising capability. (4, 8) To date, the majority of radiosensitising AuNP studies rely on treatment up to 1% wt/wt AuNP/tumour.(9) However, the practical implications of up-scaling to these concentrations for clinical use would prove prohibitive on a cost and potentially toxicity basis.(10) Furthermore, 'as-synthesized' AuNPs aggregate at physiological conditions, requiring the addition of stabilizing moieties. Polyethylene glycol (PEG) is the most widely studied due to existing regulatory approval (MHRA and EMA) and a proven ability to increase systemic circulation time. This stabilising effect is possible as PEG limits nanoparticle opsonisation through the inhibition of non-specific absorption. (11) Despite these obvious advantages, PEG also severely hinders internalization, an effect referred to as the "PEG dilemma." (12) No optimal PEG chain length has been definitively established, but ≤5000 MW PEG is thought to provide the required stability while minimising the negative impact on endocytosis. (13) Herein, AuNPs were synthesised and co-functionalized with 5000 MW PEG, conferring stability and improved in vivo circulation times. Furthermore, synthetic derivatives of two natural peptides were used to overcome biological barriers. (14) The peptide RME derived from viral origins, contains a string of cationic lysine residues that promote internalization. Furthermore, the free thiol group within the N-terminal cysteine residue permits robust chemisorption (enthalpy ~126 kJ/mol) of the RME peptide to the AuNP surface. (15, 16) A second peptide H5WYG remains unprotonated at physiological pH, but undergoes profound conformational restructuring due to histidyl protonation under mildly acidic conditions found within the endosome. (17) This remodeling effect is further enhanced by the presence of a tryptophan-histidine bridge (WH) that confers strong alpha-helicity capable of destabilizing the endosomal membrane in a process known as the proton sponge effect. (18, 19) Combining these functional groups, we aimed to develop a AuNP capable of conferring significant radiation enhancement at a clinically relevant concentration.
Breast cancer was chosen as an exemplar tumour model based on the results of the EORTC trial and the recommendations of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (20, 21) The EORTC trial assessed the clinical benefit of a radiation boost (16 Gy) following conventional breast conserving therapy plus radiotherapy (50 Gy). (21) The results indicate that increasing the total administered dose by 30%, results in 39.2% reduction in the 10-year recurrence rate, significantly reducing the requirement for salvage mastectomies.
While encouraging, patients receiving the radiotherapy boost had a 2.6 fold greater risk of developing severe fibrosis and an elevated risk of ischemic heart disease, particularly for patients with cancer of the left breast. Darby et al (2013) reported that the mean dose to the heart was 6.6 Gy for women with tumours in the left breast, and that with each subsequent 1 Gy increase to the heart the risk of a major coronary event increased by 7.4%. (22) In this context AuNPs hold real potential, delivering increased radiosensitivity, while limiting physical radiation dose delivered. Further evidence for this was recently presented in vivo where breast tumours doped with 0.5 mg AuNP generated radiation dose enhancement equivalent to three doses of cisplatin (IC25 -4 mg/kg) without inducing intrinsic toxicity. (23) While our study focused on breast cancer, most tumours routinely treated with IR (ionising radiation) could potentially benefit, with AuNP radiosensitisation previously demonstrated in prostate, glioma and head and neck cancers.(24-26) Herein we provide a robust characterisation of AuNP synthesis and physical properties, as well as comprehensive assessment of stability and biological efficacy in vitro and in vivo including an insight into key radiosensitising mechanisms.
Methods

Materials
Chloroauric acid (HAuCl4.3H2O), PEG-SH (5000 MW) and sodium citrate were obtained from Sigma Aldrich (UK). The 0.01 wt.% chlorauric acid and 1 wt.% sodium citrate solutions were prepared using distilled water. RME peptide (sequence CKKKKKKSEDEYPYVPN) and H5WYG peptide (sequence GCGLFHAIAHFIHGGWHGHHGWYG) were purchased from BIOMATIK (USA). Peptides were synthesised to >99% purity, lyophilized in acetate salt with trifluoracetic acid constituting <1%.
Synthesis and Functionalization of gold nanoparticles
The Turkevitch/Frens AuNP synthesis method has been widely employed since the 1950's and a schematic is available in Zhoa et al. (27, 28) Briefly, 13 ± 2.15 nm (Supplementary Figure 1) citrate capped nanoparticles (AuNP-C) were produced by reducing 400 ml of boiling 0.01 wt.% chloroauric acid using 9 ml of 1 wt.% sodium citrate solution, as described in our previous publication. (29) To prepare 50% PEG capped AuNPs (AuNP-P), 10.68 μg/ml 5000MW PEG-SH was dissolved in 1 ml distilled water and added to the citrate reduced AuNPs. (30) The colloid/PEG solution was vigorously mixed for 8 h at room temperature allowing PEG/citrate exchange. Excess unconjugated PEG was removed by centrifugation (12000 RCF for 90 min).
Single peptide preparations (50% PEG / 50% peptide) functionalised with RME (AuNP-R) or H5WYG (AuNP-H5) were produced by adding 4.4 and 7.86 μg/ml of free peptide respectively.
Finally the co-functionalised preparation (termed dual peptide, AuNP-DP) was produced by adding 2.23 μg/ml of free RME peptide (dissolved in 1 ml of distilled water) and 3.93 μg/ml of H5WYG peptide to AuNP-P, mixed for 8 h, then washed to remove excess unconjugated peptide.
AuNP characterization
Nanoparticle size, charge and polydispersity were determined by dynamic light scattering (DLS) using a Malvern Nano Zetasizer ZS Series. Fourier transform infrared spectroscopy (FTIR) spectra were recorded in the range of 400-4000 cm -1 at a resolution of 4 cm -1 on a Varian 640-IR FTIR spectrometer. UV-Visible spectra were recorded using a Perkin Elmer Lambda 35 in the range 400-600 nm at 0.1 nm increments. Stress testing AuNP stability in high ionic solutions (1 M NaCl) was conducted by UV/Vis measurement of the characteristic plasmon peak over 24 h. Serum stably was established using DLS following a 24 h incubation medium containing 10% or 40% foetal calf serum.
Cell culture and AuNP delivery
MDA-MB-231 and MCF-7 human breast cancer cell lines were cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Normal breast epithelial cell line MCF-10A were cultured in DMEM/F-12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin and 10 µg/ml insulin. Cells were maintained at 37°C, 95% air/5% CO2 and sub-cultured every 3-4 days to maintain exponential growth. Unless specifically stated, all AuNP treatments were performed at 25 µg/ml for 24 h.
Inductively coupled plasma atomic absorption spectroscopy (ICP-AAS)
AuNP uptake was quantified using ICP-AAS as previously described. (24) Data is normalized to AuNP-P, to represent the fold-increase in nanoparticle internalisation following peptide conjugation.
In Vitro Cytotoxicity
AuNP induced toxicity was assessed using both the WST-1 assay and xCELLigence platform.
Briefly, 2x10 4 AuNP treated (25 µg/ml) cells were washed twice with PBS prior to the addition of 10% WST-1 for 4 h. Cell viability was determined by changes in absorbance at ʎ 440 nm relative to untreated controls. Concentration dependent toxicity was assessed using the xCELLigence platform as previously described (ACEA, US). (31)
CytoViva analysis of cells with internalized AuNP-DP
Cytoviva enhanced darkfield/hyperspectral microscopy permits the optical observation and spectral confirmation of nanoparticles, where AuNPs appear bright due to their high scattering cross-section. Hyperspectral imaging permits capture and recording of unique reflectance spectra (compared against untreated controls) on a pixel-by-pixel basis, providing confirmation of internalisation and intracellular localization. 3x10 4 cells were seeded into a 4-well chamber slide (Corning-US), treated with AuNPs, then fixed with 10% Formalin.
AuNP induced radiosensitivity
Survival fractions were generated by clonogenic assay, as previously described. DNA Damage Analysis 7.5 x10 4 cells were seeded, left to adhere, then treated with AuNPs for 24 h. AuNP treated cells were irradiated (1 Gy), then returned to the incubator for 4 h allowing partial DNA repair. Cells were fixed and permeabilised using 100% methanol at -20C, then blocked using 2% FBS in PBS at room temperature. Primary H2aX (1:300 in PBS) and secondary antibody (1:400 in PBS) incubations were performed at room temperature prior to mounting using VECTASHIELD plus DAPI at 0.75 µg/ml. H2aX foci for 100 cells per condition were scored.
Radiation and AuNP induced Reactive Oxygen Species (ROS)
In the presence of ROS 2',7'-dichlorofluorescin diacetate (DCFDA) is oxidised to fluorescent 2', 7'-dichlorofluorescein (DCF). 1.5 x 10 4 cells were seeded and allowed to adhere for 24 h.
Medium containing 5 μM DCFDA was added for 40 min allowing internalisation, and replaced with fresh media. Cells were irradiated with a 2 Gy dose and ROS levels measured using a fluorescent plate reader at 495/529 nm. To detect ROS levels following AuNP and IR treatment, cells were first pre-treated with AuNP for 2 h, during the last 40 min 5 μM DCFDA was added.
Western Blotting for SOD2
Whole cell lysates were collected by adding 150 μl Laemmli buffer (Sigma) to adherent cells following AuNP and/or 2 Gy IR treatments. Western blotting was then performed as previously described.(32) Primary antibodies were used at 1:1000 (anti-SOD2 and anti-β-actin, Thermo-Fisher Scientific) in 5% blocking buffer at 4 °C. Secondary antibody was used at 1:5000 in 1% blocking buffer for 1 h. Densitometry analysis was performed using Image J.
In vivo tumour growth delay model
All animal experiments were carried out in accordance with QUB institutional regulations and the Animal (Scientific Procedures) Act of 1986, conforming to the current United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines. BALB/C SCID mice (6-8 week-old) were used to develop a sub-cutaneous (s.c.) MDA-MB-231 tumour xenograft model. Mice were anesthetized using isoflurance (3% in O2) and 1.5x10 6 MDA-MB-231 cells injected into the rear dorsum. Tumours were grown to approximately 100 mm 3 , at which point animals were randomly assigned to one of four experimental groups; untreated, AuNP-DP only, IR only (4 Gy), AuNP-DP + 4 Gy. AuNP-DP (6 mg/kg) was delivered by direct intra-tumoural injection equating to 150 g Au per 25 g animal. In vivo radiation treatments were delivered using a small animal radiation research platform (SARRP -Xstrahl). Tumours were imaged by CT and treated using two parallel beams delivering 4 Gy 225 kVp x-rays. Upon recruitment to the study animal weights and tumour volume were recorded three times weekly. Tumour volume was measured in three orthogonal dimensions.
Experimental endpoints for individual animals were defined by tumor volume exceeding 400 mm 3 or animals losing more than 10% of their maximum body weight.
Results
AuNP Characterization
DLS was used to establish size and surface charge (Figures 1A&B) characteristics. Following PEG conjugation hydrodynamic size increases to 28.7 nm ± 0.89 nm, towards the optimal range for uptake.(5) Nanoparticle size increased slightly (AuNP-DP: 36.6 nm ± 3.07) following peptide conjugation with the AuNP-H5 preparation exhibiting the most significant increase to 45.9 ± 0.92 nm. Comparable sizing between nanoparticle preparations indicate a mixed monolayer configuration between PEG and the bioactive peptides.(29) Citrate AuNPs possess a strong negative charge at -31.5 mV, which reduces to -7.2 mV after PEG conjugation. Both the RME and H5WYG peptides alone further reduce the negative surface charge, remaining anionic. However, the combination of both peptides (AuNP-DP) yields an overall cationic particle with a net charge of 6.5 mV.
The position of surface plasmon peak shifts from 518 nm for the AuNP-C, to 521.5 for AuNP-P and further to 254.6 nm after conjunction with both peptides ( Figure 1C ). This measured upshift in peak position of 2-3 nm is consistent with AuNP functionalization.(33) Samples functionalized with PEG together with only the RME or H5WYG peptides displayed ʎmax positions of 524 and 524.3 nm respectively.
The FTIR Spectra of washed and dried, AuNP-P, RME and H5 peptides alone and AuNP-DP are shown in Figure 1D . A comparison of the FTIR spectra of AuNPs before and after PEGylation is detailed in our previous publications. (29, 30) The presence of PEG on the AuNP-P sample is confirmed by a peak at 1,106cm -1 (C-O-C stretching) and narrowing of the C-H2 peak (2,850cm -1 ) indicative of ethylene glycol moieties (29, 30, 34, 35) Peptide groups elicit characteristic amide bands in several regions. Characteristic Amide A resulting from N-H stretching vibrations at ~3500 cm -1 are evident on the spectra of the free H5WYG peptide and on the AuNP-DP sample, indicating the presence of H5WYG on the surface. A small broad peak is also visible in the spectra of the RME sample in this region. The Amide band I resonates between 1600-1700 cm -1 , is associated with C=O stretching and is sensitive to conformation.(36) Amide I peaks are observed in the H5WYG and RME spectra at 1666 and 1680 cm -1 respectively. The series of features in the 1690-1620 region on the dual peptide samples is consistent with the presence of the peptides. The spectra of the AuNP sample capped only with PEG shows no activity in this region. The presence of the RME peptide on the dual peptide sample is further supported by peaks at 982 and 850 cm -1 (N-H wagging), which are visible on the spectra of both the RME peptide and dual peptide samples.
The FTIR data combined with the UV-Vis and Zeta measurements strongly supports the successful conjunction of both peptides to the surface. This is further reinforced by Figure 3A illustrating superior internalization using AuNP-DP.
UV-vis was also used to demonstrate nanoparticle stability in strong ionic fluids (1 M NaCL) ( Figure 2A ). Importantly, both AuNP-P and AuNP-DP show no change in their UV-spectral profile over time, indicating stability in excess of physiologically relevant concentrations. In contrast AuNP-C shows a rapid reduction in absorbance almost immediately, indicative of irreversible agglomeration. Serum stability ( Figure 2B ) was assessed by changes in particle size. DLS measurements indicate significant (p<0.001) particle agglomeration of AuNP-C in medium containing 10 % serum, an effect totally abrogated following PEG conjugation.
Indeed, protection against non-specific protein absorption was also conferred peptide conjugated variants including AuNP-DP.
AuNP cellular uptake
While PEG provides effective protection against agglomeration, it is widely acknowledged to impair cell internalisation. (37) Figure 3A Biocompatibility was observed up to 300 μg/mL, after which higher exposure concentrations significantly reduced viability.
CytoViva Imaging
Intracellular distribution was investigated using enhanced darkfield and hyperspectral imaging (HSI) (Figure 4 ). Enhanced darkfield images (Panels A,C,E) of high intensity bright areas potentially represents AuNPs, absent from control samples. Clusters are located within the perinuclear region of the cell and more diffusely distributed throughout the cytoplasm. Using pixelby-pixel hyperspectral filtering against untreated controls, false positives are eliminated, producing a spectral map confirming the intracellular locality of AuNP-DP (mapped in red).
Hyperspectral images generate maximum intensity projected images which compress z-plane
data, therefore AuNPs which appear to co-localise with the cell nucleus are likely cytoplasmic, located above or below the nucleus.
In vitro AuNP Induced Radiosensitivity
Colony forming assays were used to determine the radiosensitising potential of the AuNP preparations ( Figure 5 A-C). In normal MCF-10A cells, no radiation dose enhancement was observed with AuNP-P, and a modest, but significant (p=0.003) SER of 1.19 recorded using the fully functionalised AuNP-DP. Conversely, highly significant sensitisation was observed in MDA-MB-231 cells with AuNP-P and AuNP-DP generating average SERs of 1.25 (p=0.01) and 1.54 (p<0.001) respectively. Importantly, radiosensitisation was significantly increased at higher radiation doses, where a 4 Gy SER of 3.19 was obtained. In MCF-7 cells, no significant radiosensitisation was observed using the MID which incorporates data from the full survival curve. However, like the MDA-MB-231 cell, AuNP-DP significantly sensitised MCF-7 cells to higher dose fractions producing a SER of 2.57 at 6 Gy. Similar radiosensitisation survival effects, although less pronounced at higher radiation doses, were obtained using the single peptide (AuNP-R and AuNP-H5) preparations (Supplementary Figure 3A-C) .
Underpinning mechanisms
As AuNP-DP resulted in maximum nanoparticle internalisation, and the greatest radiation dose Expression levels of SOD-2 following AuNP-DP treatment gradually increased from 4 h post treatment, to a maximum 4.6 fold (p<0.01) increase 24 h post exposure ( Figure 6H) , with a similar response observed in irradiated cells doped with AuNP-DP ( Figure 6I) .
Xenograft tumour delay model
An MDA-MB-231 xenograft tumour model was used to assess the in vivo radiosensitising ability of AuNP-DP (Figure 7 A-D ). This tumour model was selected due to the underlying biology highlighted in figures 4 and 5, which indicate a likely benefit from including AuNPs. Figure 7B ). Direct inject of AuNP-DP alone had no impact on tumour growth.
Analysis of the mean tumour growth data indicate that while there was a significant difference between control and both IR only (p<0.05) and AuNP-DP + IR (p<0.001) treated animals, no significant difference between IR only and AuNP-DP +IR was observed. Similarly, Kaplan-Meier survival analysis supported this finding, with a trend (p=0.081) towards increased survival, evidenced by a separation of the IR and AuNP-DP + IR curves ( Figure 7C ). Analysis of tumour growth to 300 mm 3 reveals a different picture ( Figure 7D ). Unsurprisingly, IR significantly (p<0.05) delayed tumour growth by 3.39 days compared to untreated controls, however, in this instance AuNP-DP in combination with IR highly significantly (p<0.001) impaired tumour progression by 6.7 days relative to animals receiving 4 Gy only ( Figure 7D ). Assessing SOD-2 expression levels over 24 h revealed that it took up to 8 h post AuNP or IR treatment for SOD-2 elevation. Therefore, it is likely that the time lag between nanoparticleinduced ROS production (early event 30 min -1 h) and the cells biological response (elevated SOD-2) is sufficient to allow significant ROS driven damage.
Discussion
In the clinical context, AuNPs could be directly administered to the tumour bed after lumpectomy or mastectomy, prior to intraoperative radiotherapy. As such we elected to directly inject AuNP-DP to determine if the radiosensitising efficacy identified in vitro translated to the in vivo setting. Landmark studies highlighting the radiosensitisation potential of AuNPs have typically used in vivo dosing in excess of 2 g/Kg Au. (49, 50) However, due to the higher endocytotic potential AuNP-DP was administered at 6 mg/kg. This concentration was based on our previous study using small (<4 nm) DTDTPA-grafted AuNPs, which exhibited a lower internalisation potential.(24) A pre-determined experimental end-point of tumour volume developing to four times initial treatment volume was applied. Solely using this criteria suggests that AuNP-DP confers no statistically significant (p=0.13) advantage in terms of tumour growth delay compared to radiation alone, a result mirrored by the Kaplan Meyer survival curve ( Figure 7C : IR verses IR + AuNP-DP p=0.081 Mantel-Cox test). This result is strongly influenced by the treatment scheduling. A fixed experimental endpoint fails to account for the pronounced tumour delay observed during the first 12 days post treatment and the data presented in Figure 7D . Extrapolating from the radiation sensitivity data ( Figure 5B These investigations report the successful synthesis of a novel multifunctional AuNP that demonstrates significant internalisation and radiosensitisation. Furthermore, SOD-2 is identified as a key mediator of inherent radioresistance between cell lines. Importantly, in vitro observations translated to effective tumour growth delay in vivo. Using the example of breast cancer, the significance of the in vivo radiosensitisation should not be underestimated, given the known doubled edged sword effects conferred by a radiotherapy boost for patients with left sided breast cancer. 
